Log in

Relevant bibliographies by topics / Fansidar / Journal articles

To see the other types of publications on this topic, follow the link: Fansidar.

Journal articles on the topic 'Fansidar'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fansidar.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Azlin, Emil, Ichwan HH Batubara, Wisman Dalimunte, et al. "The effectiveness of chloroquine compared to Fansidar in treating falciparum malaria." Paediatrica Indonesiana 44, no. 1 (2016): 17. http://dx.doi.org/10.14238/pi44.1.2004.17-20.

Full text

Abstract:

Background The most difficult problem in eradicating malaria isthe resistance of P. falciparum to drugs. Mandailing Natal has thehighest malaria incidence in North Sumatera.Objective This study aimed to investigate the efficacy of chloro-quine and Fansidar in treating falciparum malaria.Methods A randomized double-blind study was done from April toMay 2001. Eighty-three patients with acute uncomplicated P.falciparum malaria infection were randomized into two groups.Group I (35 patients) received chloroquine and group II (48 pa-tients) received Fansidar. Blood examinations were performed onthe

APA, Harvard, Vancouver, ISO, and other styles

2

McCormack, David, and W. K. C. Morgan. "Fansidar hypersensitivity pneumonitis." British Journal of Diseases of the Chest 81 (January 1987): 194–96. http://dx.doi.org/10.1016/0007-0971(87)90140-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

LAZAR, HAROLD P. "Fansidar and Hepatic Granulomas." Annals of Internal Medicine 102, no. 5 (1985): 722. http://dx.doi.org/10.7326/0003-4819-102-5-722_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bradley, D. J., A. P. Hall, W. Peters, and D. Warhurst. "Fansidar in malaria prophylaxis." BMJ 291, no. 6488 (1985): 136. http://dx.doi.org/10.1136/bmj.291.6488.136.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hudson, J. E. "Fansidar-one man's warning." Parasitology Today 2, no. 3 (1986): 76–77. http://dx.doi.org/10.1016/0169-4758(86)90161-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

FRISSEN, P. H. J. "Fansidar and Pneumocystis carinii Pneumonia." Annals of Internal Medicine 108, no. 4 (1988): 638. http://dx.doi.org/10.7326/0003-4819-108-4-638_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wejstal, Rune, Johan Lindberg, Bo-Erik Malmvall, and Gunnar Norkrans. "LIVER DAMAGE ASSOCIATED WITH FANSIDAR." Lancet 327, no. 8485 (1986): 854–55. http://dx.doi.org/10.1016/s0140-6736(86)90961-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Watt, George, Laurena P. Padre, Linda R. Tuazon, and Larry W. Laughlin. "Fansidar resistance in the Philippines." Transactions of the Royal Society of Tropical Medicine and Hygiene 81, no. 3 (1987): 521. http://dx.doi.org/10.1016/0035-9203(87)90191-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Harinasuta, T., C. Viravan, and P. Buranasin. "Parenteral Fansidar® in falciparum Malaria." Transactions of the Royal Society of Tropical Medicine and Hygiene 82, no. 5 (1988): 694. http://dx.doi.org/10.1016/0035-9203(88)90203-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Jeffrey, R. F. "Transient lupus anticoagulant and fansidar therapy." Postgraduate Medical Journal 62, no. 731 (1986): 893–94. http://dx.doi.org/10.1136/pgmj.62.731.893.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Akintunde, J. K., J. A. Ajiboye, E. O. Siemuri, and O. O. Olabisi. "Fansidar drug induces cytotoxicity in some vital tissues in a rat model: combination defensive effect of selenium and zinc capsules." Therapeutic Advances in Drug Safety 12 (January 2021): 204209862110271. http://dx.doi.org/10.1177/20420986211027101.

Full text

Abstract:

Aim: Fansidar (FAN) is widely used as an antimalarial drug, but it may cause hepatoxicity, nephrotoxicity, and neurotoxicity. Hence, the study examines the cytoprotection of selenium (Se) and zinc (Zn) tablets against FAN induced toxicity. Method: Group I was given distilled water. Groups II, III, IV, and V received 50 mg/kg FAN by gavage. Group III was co-treated with a 50 mg/kg Se tablet. Group IV was co-treated with a 50 mg/kg Zn tablet. Group V was co-treated with a 50 mg/kg Se tablet + 50 mg/kg Zn tablet. The exposure lasted for 7 days (sub-acute exposure). Result: FAN causes cytotoxicity

APA, Harvard, Vancouver, ISO, and other styles

12

McMeeking, A. A. "Chloroquine and Fansidar(R) Prophylaxis -- A Reply." Journal of Infectious Diseases 155, no. 6 (1987): 1351. http://dx.doi.org/10.1093/infdis/155.6.1351-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bath, P. M., D. A. Lillicrap, and M. Winter. "Fansidar--a treatment for AIDS-related pneumocystis?" Postgraduate Medical Journal 63, no. 740 (1987): 509–10. http://dx.doi.org/10.1136/pgmj.63.740.509-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Adams, S. J., J. Broadbent, L. M. Clayden, and C. M. Ridley. "Erythema multiforme (Stevens-Johnson) precipitated by Fansidar." Postgraduate Medical Journal 61, no. 713 (1985): 263–64. http://dx.doi.org/10.1136/pgmj.61.713.263.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

HUTOMO, RAHADI, SUTARNO SUTARNO, WIEN WINARNO, and KUSMARDI KUSMARDI. "Antimalaria assay of fruit extract of Morinda citrifolia and activity of mice (Mus musculus) macrophage after infecting it with Plasmodium berghei." Biofarmasi Journal of Natural Product Biochemistry 3, no. 2 (2005): 61–69. http://dx.doi.org/10.13057/biofar/f030206.

Full text

Abstract:

Malaria is a world wide disease. Death resulting from the disease was caused by the parasiteâ€™s resistance to the malaria drugs and the problem of immune system. The aims of the research were to know the effect of M. citrifolia fruit extract to Plasmodium berghei on total red blood cells of mice, and to know the effect of the extract on the number of intraperitoneal macrophage phagocytosing latex after infected by P. berghei. Three doses of fruit extract, 200, 150, 100 mg/kg BB were used in this study. Fansidar was used as positive control, while distilled water was used as negative control.

APA, Harvard, Vancouver, ISO, and other styles

16

Ferraroni, José J., Thomas G. Douglass, and Clarence A. Speer. "Efeito do Mycobacterium bovis BCG, lipopolissacarideo bacteriano e hidrocortisona no desenvolvimento de imunidade ao Plasmodium berghei em camundongos." Revista do Instituto de Medicina Tropical de São Paulo 28, no. 1 (1986): 36–45. http://dx.doi.org/10.1590/s0036-46651986000100007.

Full text

Abstract:

Mycobacterium bovis (BCG) aumenta significantemente o desenvolvimento da imunidade nos camundongos CFW, C57BL/6, C57BL/l0ScN e BALB/c (Nu/+) para os estágios eritrocitos do Plasmodium berghei. Camundongos tratados com BCG requerem menos ciclos de infecção com P. berghei e cura pelo Fansidar (pirimetamina + sulfadoxina) para desenvolverem imunidade sólida a este parasita do que os controles. Contudo, os animais que receberam BCG 30 dias antes do início da imunização evidenciaram uma perda precoce da imunidade adquirida para o P. berghei, quando comparado com os animais que receberam BCG 14 dias

APA, Harvard, Vancouver, ISO, and other styles

17

ZITELLI, BASIL J. "Fatal Hepatic Necrosis Due to Pyrimethamine-Sulfadoxine (Fansidar)." Annals of Internal Medicine 106, no. 3 (1987): 393. http://dx.doi.org/10.7326/0003-4819-106-3-393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Don??t write off ???Fansidar??? for falciparum malaria." Inpharma Weekly &NA;, no. 806 (1991): 4. http://dx.doi.org/10.2165/00128413-199108060-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Warhurst, D. C., A. P. Hall, and S. Tjokrosonto. "RI QUININE-FANSIDAR RESISTANT FALCIPARUM MALARIA FROM MALAWI." Lancet 326, no. 8450 (1985): 330. http://dx.doi.org/10.1016/s0140-6736(85)90376-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lindberg, Johan, Torsten Sandberg, Bengt Björkholm, and Anders Björkman. "CHLOROQUINE AND FANSIDAR RESISTANT MALARIA ACQUIRED IN ANGOLA." Lancet 325, no. 8431 (1985): 765. http://dx.doi.org/10.1016/s0140-6736(85)91315-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Bojang, K. A., G. Schneider, S. Forck, et al. "A trial of Fansidar® plus chloroquine or Fansidar® alone for the treatment of uncomplicated malaria in Gambian children." Transactions of the Royal Society of Tropical Medicine and Hygiene 92, no. 1 (1998): 73–76. http://dx.doi.org/10.1016/s0035-9203(98)90962-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

WANG, P., P. F. G. SIMS, and J. E. HYDE. "A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparum suitable for investigating Fansidar resistance." Parasitology 115, no. 3 (1997): 223–30. http://dx.doi.org/10.1017/s0031182097001431.

Full text

Abstract:

The combination of pyrimethamine and sulfadoxine (PSD or Fansidar) represents one of the most important chemo- therapeutic agents currently used to treat falciparum malaria. To investigate the molecular basis of resistance to PSD, reliable in vitro drug assays are required to permit correlation of resistance levels with different genotypes. We describe here protocols that permit accurate evaluation of IC50 values for sulfadoxine (SDX) inhibition of Plasmodium falciparum. Historically, tests for this drug have suffered from poor reproducibility and extreme variability in reported values. We hav

APA, Harvard, Vancouver, ISO, and other styles

23

Bamber, M. G., A. T. Elder, J. A. Gray, and R. A. Minns. "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." Journal of Infection 13, no. 1 (1986): 31–33. http://dx.doi.org/10.1016/s0163-4453(86)92187-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Lenox-Smith, Ian. "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." Journal of Infection 14, no. 1 (1987): 90–91. http://dx.doi.org/10.1016/s0163-4453(87)91068-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Bamber, M. G., A. T. Elder, J. A. Gray, and R. A. Minns. "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." Journal of Infection 14, no. 1 (1987): 91. http://dx.doi.org/10.1016/s0163-4453(87)91094-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Cook, G. C. "Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine." Journal of Infection 14, no. 1 (1987): 92. http://dx.doi.org/10.1016/s0163-4453(87)91120-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sendagire, Hakim, Mark Kaddumukasa, Dorothy Ndagire, et al. "Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-Fansidar as a better alternative." Acta Tropica 95, no. 3 (2005): 172–82. http://dx.doi.org/10.1016/j.actatropica.2005.06.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Strickland, G. Thomas, Hadi Hassan, Emile Fox, Mohammad Sarwar, Mohammad Pervez, and Amir A. Khaliq. "Effects of Fansidar on Chloroquine-Resistant Plasmodium falciparum in Pakistan *." American Journal of Tropical Medicine and Hygiene 35, no. 1 (1986): 61–65. http://dx.doi.org/10.4269/ajtmh.1986.35.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

FISCHL, MARGARET A. "Fansidar Prophylaxis of Pneumocystis Pneumonia in the Acquired Immunodeficiency Syndrome." Annals of Internal Medicine 105, no. 4 (1986): 629. http://dx.doi.org/10.7326/0003-4819-105-4-629_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Fansidar should be used selectively and in combination with quinine." Inpharma Weekly &NA;, no. 747 (1990): 10–11. http://dx.doi.org/10.2165/00128413-199007470-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bull, R. H., and R. C. D. Staughton. "Increased risk of cutaneous reactions to Fansidar in HIV disease." British Journal of Dermatology 123, s37 (1990): 28–29. http://dx.doi.org/10.1111/j.1365-2133.1990.tb04428.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Langtry, J. A., J. I. Harper, R. C. Staughton, and P. Barrington. "Erythroderma resembling sezary syndrome after treatment with Fansidar and chloroquine." BMJ 292, no. 6528 (1986): 1107–8. http://dx.doi.org/10.1136/bmj.292.6528.1107-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kizito, Omona, Mulungi Damali, Twesigye Edson, Tukamuhabwa Joram, Rukaari Medard, and Bosco Ninsiima John. "Factors Influencing Uptake of IPTp3+ Among Pregnant Women Attending ANC in Mawokota North Health Sub District, Mpigi District, Uganda." Cognizance Journal of Multidisciplinary Studies 1, no. 3 (2021): 17–29. https://doi.org/10.47760/cognizance.2021.v01i03.002.

Full text

Abstract:

<strong><em>Background</em></strong><em>: Annually, approximately 125 million pregnancies occur globally in malaria endemic areas. 25 million pregnant women are at risk for malaria which accounts for over 10,000 maternal and 200,000 neonatal deaths annually. WHO recommends initiation of IPT3+ in malaria endemic areas beginning with second trimester throughout pregnancy? However, uptakes of IPT3+ remain low in many countries, for instance in Uganda, the coverage of IPT3+ remains low at 66%. </em> <strong><em>Objectives:</em></strong><em> The study objectives were; to determine the socio-demogra

APA, Harvard, Vancouver, ISO, and other styles

34

Chishimba, Norris Chileshe, Crecious Phiri, and Gabriel Mpundu. "Identifying Factors Associated with Low Use of Intermittent Malaria Preventive Treatment in Pregnancy: Healthy Moms and Babies Program." International Journal of Science and Healthcare Research 9, no. 4 (2024): 254–62. http://dx.doi.org/10.52403/ijshr.20240432.

Full text

Abstract:

Malaria during pregnancy remains a major public health problem in Sub-Saharan Africa. Current strategies to prevent malaria in pregnancy and promote health include the use of insecticide-treated bed nets and intermittent preventive treatment in pregnancy (IPTp). Despite the availability of IPTp service in all health clinics in Zambia, Lufwanyama district has continued recording low utilisation of this service. The purpose of this study was to determine factors associated with the low utilisation of IPT of malaria among pregnant women attending antenatal (ANC) clinics in Lufwanyama. A cross-sec

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Risk of severe adverse skin reactions to Fansidar (Rm) is acceptable." Reactions Weekly &NA;, no. 442 (1993): 2. http://dx.doi.org/10.2165/00128415-199304420-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Stürchler, Dieter, Marie Louise Mittelholzer, and Lydia Kerr. "How Frequent are Notified Severe Cutaneous Adverse Reactions to Fansidar®?" Drug Safety 8, no. 2 (1993): 160–68. http://dx.doi.org/10.2165/00002018-199308020-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Edstein, Michael D. "Pharmacokinetics of Sulfadoxine and Pyrimethamine after Fansidar® Administration in Man." Chemotherapy 33, no. 4 (1987): 229–33. http://dx.doi.org/10.1159/000238499.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Abou-Eisha, A., and M. Afifi. "Genotoxic evaluation of the antimalarial drug, fansidar, in cultured human lymphocytes." Cell Biology and Toxicology 20, no. 5 (2004): 303–11. http://dx.doi.org/10.1007/s10565-004-5352-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Selby, C. D., E. J. Ladusans, and P. G. Smith. "Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar)." BMJ 290, no. 6462 (1985): 113–14. http://dx.doi.org/10.1136/bmj.290.6462.113-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Wolday, Dawit, Tsehaye Kibreab, Daraus Bukenya, and Richard Hodes. "Meningococcal Meningitis in Patients with Falciparum Malaria." Tropical Doctor 26, no. 4 (1996): 157–59. http://dx.doi.org/10.1177/004947559602600405.

Full text

Abstract:

Between October 1994 and January 1995 a field hospital saw nine cases of falciparum malaria associated with meningococcal meningitis among Rwandan patients residing in Kibumba refugee camp in Goma, Zaire. All except one presented with signs and symptoms suggestive of meningeal irritation; all but one responded to intravenous quinine and chloramphenicol or ampicillin. Two had recrudescence of malaria and responded to treatment with pyrimethamine-sulphadoxine (Fansidar). There were no sequelae seen. Meningococcal meningitis is uncommon but frequently fatal if it occurs in patients with falciparu

APA, Harvard, Vancouver, ISO, and other styles

41

Rao, V. Koneti, Kennichi C. Dowdell, Faith Dugan, et al. "Pyrimethamine Does Not Diminish Lymphoproliferation in MRL/lpr−/− Mice and Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)." Blood 106, no. 11 (2005): 2396. http://dx.doi.org/10.1182/blood.v106.11.2396.2396.

Full text

Abstract:

Abstract ALPS is an inherited disorder of lymphocyte apoptosis leading to childhood onset of chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma in a subset of patients with mutations in the intracellular domain of Fas (ALPS Type Ia). Similarly, MRL/lpr −/− mice are homozygous for Fas mutations and develop massive lymphadenopathy and splenomegaly associated with hypergammaglobulinemia, glomerulonephritis, and expansion of TCR αβ+, CD4−/CD8−double-negative (DN) T cells that are pathognomonic of ALPS. There remain no proven therapies for the lymphoprolife

APA, Harvard, Vancouver, ISO, and other styles

42

Jimmy, E. O. "Durational Therapeutic Dose of Fansidar: A Functional Index in Its Antidiabetic Properties." Journal of Biosciences and Medicines 07, no. 01 (2019): 23–28. http://dx.doi.org/10.4236/jbm.2019.71003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gadir, Warda S. Abdel, Mohy Edeen, D. Abu Alazaim, Amel O. Bakhiet, and I. M. T. Fadlalla. "Effects of Quinine and Fansidar and Their Combination on Bovans-Type Chicks." Journal of Pharmacology and Toxicology 1, no. 4 (2006): 383–88. http://dx.doi.org/10.3923/jpt.2006.383.388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Rombo, Lars, Johan Stenbeck, HansO Lobel, CarlosC Campbell, Marguarite Papaioanou, and KirkD Miller. "DOES CHLOROQUINE CONTRIBUTE TO THE RISK OF SERIOUS ADVERSE REACTIONS TO FANSIDAR?" Lancet 326, no. 8467 (1985): 1298–99. http://dx.doi.org/10.1016/s0140-6736(85)91574-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Jeffrey, R. F. "Drug Points: Erythroderma resembling Sezary syndrome after treatment with Fansidar and chloroquine." BMJ 292, no. 6536 (1986): 1672. http://dx.doi.org/10.1136/bmj.292.6536.1672-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

HIOKI, ATSUSHI, and HIROSHI OHTOMO. "Changes of blood oxygen affinity in Fansidar-treated mice infected with Plasmodium berghei." Japanese Journal of Tropical Medicine and Hygiene 15, no. 1 (1987): 17–23. http://dx.doi.org/10.2149/tmh1973.15.17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

ELLIS-PEGLER, R. B., N. J. BEECHING, M. EALES, A. G. FRASER, and A. U. WELLS. "FANSIMEF [FANSIDAR PLUS MEFLOQUINE] IS EFFECTIVE TREATMENT FOR IMPORTED MALARIA IN NEW ZEALAND." Australian and New Zealand Journal of Medicine 18, no. 5 (1988): 733–34. http://dx.doi.org/10.1111/j.1445-5994.1988.tb00166.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Harinasuta, T., R. Lasserre, D. Bunnag, R. Leimer, and S. Vinijanont. "TRIALS OF MEFLOQUINE IN VIVAX AND OF MEFLOQUINE PLUS 'FANSIDAR' IN FALCIPARUM MALARIA." Lancet 325, no. 8434 (1985): 885–88. http://dx.doi.org/10.1016/s0140-6736(85)91670-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Miller, Kirk D., Joel N. Kuritsky, Hans O. Lobel, Robert Stern, Richard F. Satriale, and Carlos C. Campbell. "Severe Cutaneous Reactions among American Travelers Using Pyrimethamine-Sulfadoxine (Fansidar®) for Malaria Prophylaxis." American Journal of Tropical Medicine and Hygiene 35, no. 3 (1986): 451–58. http://dx.doi.org/10.4269/ajtmh.1986.35.451.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Miller, K. D., H. O. Lobel, M. Pappaioanou, L. C. Patchen, and F. C. Churchill. "Failures of Combined Chloroquine and Fansidar(R) Prophylaxis in American Travelers to East Africa." Journal of Infectious Diseases 154, no. 4 (1986): 689–91. http://dx.doi.org/10.1093/infdis/154.4.689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!